Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-23T10:50:44.312Z Has data issue: false hasContentIssue false
  • English
  • Français

Association of the leucine-7 to proline-7 variation in the signal sequence of neuropeptide Y with major depression

Published online by Cambridge University Press:  24 June 2014

Pernille Koefoed ,
David P.D. Woldbye ,
Thomas v. O. Hansen ,
Lene F. Eplov ,
Søren H. Christiansen ,
Ole Mors ,
Lars V. Kessing ,
Thomas Werge ,
Katja Kaipio  and
Ullamari Pesonen
...Show all authors
Pernille Koefoed*
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
David P.D. Woldbye
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Thomas v. O. Hansen
Affiliation:
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Lene F. Eplov
Affiliation:
Research Centre for Prevention and Health, Copenhagen University Hospital Glostrup, Glostrup, Denmark and Research Unit for Psychiatric Rehabilitation, Mental Health Centre Ballerup, Ballerup, Denmark
Søren H. Christiansen
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
Ole Mors
Affiliation:
Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark
Lars V. Kessing
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Thomas Werge
Affiliation:
Research Institute of Biological Psychiatry, Mental Health Centre St. Hans Hospital, Roskilde, Denmark
Katja Kaipio
Affiliation:
Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
Ullamari Pesonen
Affiliation:
Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland
Thomas Fahmy
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Erling Mellerup
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
Klaus D. Jakobsen
Affiliation:
Research Institute of Biological Psychiatry, Mental Health Centre St. Hans Hospital, Roskilde, Denmark Mental Health Centre Hvidovre, Hvidovre, Denmark
Elsebeth S. Hansen
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Gitte M. Knudsen
Affiliation:
Center for Integrated Molecular Brain Imaging, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Jens D. Bukh
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Camilla Bock
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Camilla Lindberg
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
Ann S. Kristensen
Affiliation:
Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark
Henrik Dam
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Merete Nordentoft
Affiliation:
Mental Health Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark
Thomas D. Als
Affiliation:
Centre for Psychiatric Research, Aarhus University Hospital, Risskov, Denmark
August G. Wang
Affiliation:
Mental Health Centre Amager, Copenhagen, Denmark
Ulrik Gether
Affiliation:
Molecular Neuropharmacology Group and Center for Pharmacogenomics, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
Jens F. Rehfeld
Affiliation:
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Tom G. Bolwig
Affiliation:
Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
*
Pernille Koefoed, Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen & Mental Health Centre Copenhagen, Rigshospitalet O-6102, 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. Tel.: +45 3545 6113; Fax: +45 3539 3546; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Extract

Objective: There is clear evidence of a genetic component in major depression, and several studies indicate that neuropeptide Y (NPY) could play an important role in the pathophysiology of the disease. A well-known polymorphism encoding the substitution of leucine to proline in the signal peptide sequence of NPY (Leu7Pro variation) was previously found to protect against depression. Our study aimed at replicating this association in a large Danish population with major depression.

Method: Leu7Pro was studied in a sample of depressed patients and ethnically matched controls, as well as psychiatric disease controls with schizophrenia. Possible functional consequences of Leu7Pro were explored in vitro.

Results: In contrast to previous studies, Pro7 appeared to be a risk allele for depression, being significantly more frequent in the depression sample (5.5%, n = 593; p = 0.009; odds ratio, OR: 1.46) as compared to ethnically matched controls (3.8%, n = 2912), while schizophrenia patients (4.1%, n = 503) did not differ. In vitro, the Pro7 substitution appeared to be associated with reduced levels of NPY without affecting its mRNA level.

Conclusion: The Leu7Pro variation may increase the risk of major depression, possibly by affecting the biosynthesis of NPY.

Keywords

candidate gene approachcase-control association studyNPY Leu7Promajor depression
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 24 , Issue 2 , April 2012 , pp. 81 - 90
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kessing, LV.Gender differences in patients presenting with a single depressive episode according to ICD-10. Soc Psychiatry Psychiatr Epidemiol 2005;40:197–201.CrossRefGoogle ScholarPubMed
2.Levinson, DF.The genetics of depression: a review. Biol Psychiatry 2006;60:84–92.CrossRefGoogle ScholarPubMed
3.Redrobe, JP, Dumont, Y, Quirion, R.Neuropeptide Y (NPY) and depression: from animal studies to the human condition. Life Sci 2002;71:2921–2937.CrossRefGoogle Scholar
4.Husum, H, Vasquez, PA, Mathe, AA.Changed concentrations of tachykinins and neuropeptide Y in brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 2001;24:183–191.CrossRefGoogle ScholarPubMed
5.Mathé, AA, Jimenez, PA, Theodorsson, E, Stenfors, C.Neuropeptide Y, neurokinin A and neurotensin in brain regions of Fawn-Hooded “depressed”, Wistar, and Sprague-Dawley rats. Effects of electroconvulsive stimuli. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:529–546.CrossRefGoogle ScholarPubMed
6.Jimenez-Vasquez, PA, Mathé, AA, Thomas, JD, Riley, EP, Ehlers, CL.Early maternal separation alters neuropeptide Y concentrations in selected brain regions in adult rats. Brain Res Dev Brain Res 2001;131:149–152.Google Scholar
7.Caberlotto, L, Fuxe, K, Overstreet, DH, Gerrard, P, Hurd, YL.Alterations in neuropeptide Y and Y1 receptor mRNA expression in brains from an animal model of depression: region specific adaptation after fluoxetine treatment. Brain Res Mol Brain Res 1998;59:58–65.CrossRefGoogle ScholarPubMed
8.Heilig, M, Wahlestedt, C, Ekman, R, Widerlöv, E.Antidepressant drugs increase the concentration of neuropeptide Y (NPY)-like immunoreactivity in the rat brain. Eur J Pharmacol 1988;147:465–467.CrossRefGoogle ScholarPubMed
9.Mathé, AA, Jousisto-Hanson, J, Stenfors, C, Theodorsson, E.Effect of lithium on tachykinins, calcitonin gene-related peptide, and neuropeptide Y in rat brain. J Neurosci Res 1990;26:233–237.CrossRefGoogle ScholarPubMed
10.Stenfors, C, Theodorsson, E, Mathé, AA.Effect of repeated electroconvulsive treatment on regional concentrations of tachykinins, neurotensin, vasoactive intestinal polypeptide, neuropeptide Y, and galanin in rat brain. J Neurosci Res 1989;24:445–450.CrossRefGoogle ScholarPubMed
11.Christensen, DZ, Olesen, MV, Kristiansen, H, Mikkelsen, JD, Woldbye, DPD.Unaltered neuropeptide Y (NPY)-stimulated [35S]GTPγS binding suggests a net increase in NPY signalling after repeated electroconvulsive seizures in mice. J Neurosci Res 2006;84:1282–1291.CrossRefGoogle ScholarPubMed
12.Mikkelsen, JD, Woldbye, DPD.Accumulated increase in neuropeptide Y and somatostatin gene expression of the rat in response to repeated electroconvulsive stimulation. J Psychiatr Res 2006;40:153–159.Google Scholar
13.Husum, H, Mikkelsen, JD, Hogg, S, Mathé, AA.Mørk, A.Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology 2000;39:1463–1473.CrossRefGoogle ScholarPubMed
14.Redrobe, JP, Dumont, Y, Fournier, A, Quirion, R.The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test. Neuropsychopharmacology 2002;26: 615–624.Google Scholar
15.Heilig, M, Zachrisson, O, Thorsell, A et al. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 2004;38:113–121.CrossRefGoogle ScholarPubMed
16.Widerlöv, E, Lindstrom, LH, Wahlestedt, C, Ekman, R.Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J Psychiatr Res 1988;22:69–79.Google Scholar
17.Bannon, AW, Seda, J, Carmouche, M et al. Behavioral characterization of neuropeptide Y knockout mice. Brain Res 2000;868:79–87.Google Scholar
18.Sørensen, G, Lindberg, C, Wörtwein, G, Bolwig, TG, Woldbye, DPD.Different roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res 2004; 77:723–729.Google Scholar
19.Zhou, Z, Zhu, G, Hariri, AR et al. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008;452:997–1001.CrossRefGoogle ScholarPubMed
20.Karvonen, MK, Pesonen, U, Koulu, M et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med 1998;4:1434–1437.CrossRefGoogle Scholar
21.Okubo, T, Harada, S.Polymorphism of the neuropeptide Y gene: an association study with alcohol withdrawal. Alcohol Clin Exp Res 2001;25(6 Suppl):59S–62S.Google Scholar
22.Itokawa, M, Arai, M, Kato, S et al. Association between a novel polymorphism in the promotor region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 2003;347:202–204.CrossRefGoogle ScholarPubMed
23.Mottagui-Tabar, S, Prince, JA, Wahlestedt, C, Zhu, G, Goldman, D, Heilig, M.A novel single nucleotide polymorphism of the neuropeptides Y (NPY) gene associated with alcohol dependence. Alcohol Clin Exp Res 2005;29: 702–707.Google Scholar
24.Niskanen, L, Karvonen, MK, Valve, R et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin Endocrinol Metab 2000;85:2266–2269.Google Scholar
25.Niskanen, L, Voutilainen-Kaunisto, R, Terasvirta, M et al. Leucine 7 to proline 7 polymorphism in the neuropeptide Y gene is associated with retinopathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2000;108:235–236.CrossRefGoogle ScholarPubMed
26.Lappalainen, J, Kranzler, HR, Malison, R et al. A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry 2002;59:825–831.CrossRefGoogle Scholar
27.Kauhanen, J, Karvonen, MK, Pesonen, U et al. Neuropeptide Y polymorphism and alcohol consumption in middle-aged men. Am J Med Genet 2000;93:117–121.Google Scholar
28.Sjöholm, lk, Melas, PA, Forsell, Y, Lavebratt, C.PreproNPY Pro7 protects against depression despite exposure to environmental risk factors. J Affect Disord 2009;118: 124–130.CrossRefGoogle ScholarPubMed
29.Bosker, FJ, Hartman, CA, Nolte, IM et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 2011;16: 516–532.Google Scholar
30.Kessing, LV, Jørgensen, OS.Apolipoprotein E-ε4 frequency in affective disorder. Biol Psychiatry 1999;45: 430–434.CrossRefGoogle Scholar
31.Mellerup, E, Bennike, B, Bolwig, T et al. Platelet serotonin transporters and the transporter gene in control subjects, unipolar patients and bipolar patients. Acta Psychiatr Scand 2001;103:229–233.CrossRefGoogle ScholarPubMed
32.Haugboel, S, Pinborg, LH, Arfan, HM et al. Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging 2007;34:910–915.CrossRefGoogle Scholar
33.Jørgensen, T, Borch-Johnsen, K, Thomsen, TF et al. A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99. Eur J Cardiovasc Prev Rehabil 2003;10:377–386.Google Scholar
34.Lindberg, C, Koefoed, P, Hansen, ES et al. No association between the – 399 C>T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population. Acta Psychiatr Scand 2006; 113:54–58.Google Scholar
35.Koefoed, P, Hansen, TVO, Woldbye, DPD et al. An intron 1 polymorphism in the CCK-A receptor gene associated with schizophrenia in males. Acta Psychiatr Scand 2009; 120:281–287.CrossRefGoogle ScholarPubMed
36.Hansen, T, Olsen, L, Lindow, M et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS One 2007;12:e873.Google Scholar
37.Rehfeld, JF.Radioimmunochemical analysis of neuropeptides based on general characteristics of the analyte. Trends Analyt Chem 1989;8:102–106.CrossRefGoogle Scholar
38.Hällström, T, Damström-Thakker, K, Forsell, Y, Lundberg, I, Tinghög, P. The Part study. A population based study of mental health in the Stockholm county: study design. 2003. http://www.folkhalsoguiden.se/upload/Psykisk%20H%c3%a4lsa/PARTs%20tekniska%20rapport.pdf [accessed on April 2011].Google Scholar
39.Ding, B.Distribution of the NPY 1128C allele frequency in different populations. J Neural Transm 2003;110: 1199–1204.Google Scholar
40.Domschke, K, Dannlowski, U, Hohoff, C et al. Neuropeptide Y (NPY) gene: impact on emotional processing and treatment response in anxious depression. Eur Neuropsychopharmacol 2010;20:301–309.Google Scholar
41.Mickey, BJ, Zhou, Z, Heitzeg, MM et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 2011;68:158–166.Google Scholar
42.Hegde, RS, Bernstein, HD.The surprising complexity of signal sequences. Trends Biochem Sci 2006;31:563–571.CrossRefGoogle ScholarPubMed
43.Fitches, AC, Appleby, R, Lane, DA, De, SV, Leone, G, Olds, RJ.Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood 1998;92: 4671–4676.Google Scholar
44.Lanza, F, De La Salle, C, Baas, MJ et al. A Leu7Pro mutation in the signal peptide of platelet glycoprotein (GP)IX in a case of Bernard-Soulier syndrome abolishes surface expression of the GPIb-V-IX complex. Br J Haematol 2002;118:260–266.Google Scholar
45.Pidasheva, S, Canaff, L, Simonds, WF, Marx, SJ, Hendy, GN.Impaired cotranslational processing of the calcium-sensing receptor due to signal peptide missense mutations in familial hypocalciuric hypercalcemia. Hum Mol Genet 2005;14:1679–1690.CrossRefGoogle ScholarPubMed
46.Ding, B, Kull, B, Liu, Z et al. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul Pept 2005;127:45–53.CrossRefGoogle ScholarPubMed
47.Mitchell, GC, Wang, Q, Ramamoorthy, P, Whim, MD. A common single nucleotide polymorphism alters the synthesis and secretion of neuropeptide Y. J Neurosci 2008;28: 14428–14434.CrossRefGoogle ScholarPubMed
48.Kallio, J, Pesonen, U, Jaakola, U, Karvonen, MK, Helenius, H, Koulu, M.Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro. J Clin Endocrinol Metab 2003;88:3278–3283.Google Scholar
49.Jaakkola, U, Kuusela, T, Jartti, T et al. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test. J Clin Endocrinol Metab 2005;90: 3646–3652.CrossRefGoogle ScholarPubMed
50.Kallio, J, Pesonen, U, Kaipio, K et al. Altered intracellular processing and release of neuropeptides Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J 2001;15: 1242–1244.CrossRefGoogle ScholarPubMed
51.Heilig, M.The NPY system in stress, anxiety and depression. Neuropeptides 2004;38:213–224.Google Scholar
52.Ishida, H, Shirayama, Y, Iwata, M et al. Infusion of neuropeptide Y into CA3 region of hippocampus produces antidepressant-like effect via Y1 receptor. Hippocampus 2007;17:271–280.CrossRefGoogle ScholarPubMed
53.Nikisch, G, Agren, H, Eap, CB, Czernik, A, Baumann, P, Mathé, AA.Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005;8: 403–410.Google Scholar